Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['ovarian', 'sutro']
 presented findings from a phase i dose-expansion study of luveltamab tazevibulin (luvelta) in patients with advanced ovarian cancer during the ongoing 2023 conference in an oral abstract session. for a more detailed analysis, visit: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry